U.S. markets closed
  • S&P Futures

    4,392.75
    +8.75 (+0.20%)
     
  • Dow Futures

    34,212.00
    +83.00 (+0.24%)
     
  • Nasdaq Futures

    15,190.50
    +27.00 (+0.18%)
     
  • Russell 2000 Futures

    2,219.50
    +4.60 (+0.21%)
     
  • Crude Oil

    72.03
    -0.20 (-0.28%)
     
  • Gold

    1,765.30
    -13.50 (-0.76%)
     
  • Silver

    22.65
    -0.26 (-1.14%)
     
  • EUR/USD

    1.1693
    -0.0003 (-0.02%)
     
  • 10-Yr Bond

    1.3360
    +0.0120 (+0.91%)
     
  • Vix

    20.87
    -3.49 (-14.33%)
     
  • GBP/USD

    1.3619
    -0.0001 (-0.01%)
     
  • USD/JPY

    109.8450
    +0.0670 (+0.06%)
     
  • BTC-USD

    43,277.32
    +2,651.69 (+6.53%)
     
  • CMC Crypto 200

    1,088.58
    +48.10 (+4.62%)
     
  • FTSE 100

    7,083.37
    +102.39 (+1.47%)
     
  • Nikkei 225

    29,639.40
    -200.31 (-0.67%)
     

Infinity Announces the Date of Its Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer, will host a conference call on Tuesday, March 16, 2021 at 4:30 p.m. ET to report its financial results for the fourth quarter and full year 2020 financial results and provide an update on eganelisib development.

Conference Call & Webcast Details

Date:

March 16, 2021

Time:

4:30 pm Eastern Time

Toll Free:

(877) 316-5293

International:

(631) 291-4526

Conference ID:

7174736

Webcast:

https://edge.media-server.com/mmc/p/24t7wsio

A live webcast of the conference call can be accessed in the Investors/Media section of Infinity's website at www.infi.com. An archived version of the webcast will be available on Infinity's website for 30 days.

About Infinity and eganelisib

Infinity is a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer, in multiple clinical studies. MARIO-275 is a global, randomized, placebo-controlled study of eganelisib combined with Opdivo® in I/O naïve urothelial cancer. MARIO-3 is the first eganelisib combination study in front-line advanced cancer patients and is evaluating eganelisib in combination with Tecentriq® and Abraxane® in front-line TNBC and in combination with Tecentriq and Avastin® in front-line RCC. In collaboration with Arcus Biosciences, Infinity is evaluating a checkpoint inhibitor-free, novel combination regimen of eganelisib plus etrumadenant (dual adenosine receptor antagonist) plus Doxil® in advanced TNBC patients. With these studies Infinity is evaluating eganelisib in the anti-PD-1 refractory, I/O-naïve, and front-line and second line settings. For more information on Infinity, please refer to Infinity's website at www.infi.com.

Opdivo® is a registered trademark of Bristol Myers Squibb.
Tecentriq® is a registered trademark of Genentech, Inc.
Abraxane® is a registered trademark of Abraxis BioScience, LLC., a wholly owned subsidiary of Bristol Myers Squibb Company.
Avastin® is a registered trademark of Genentech, Inc.
Doxil® is a registered trademark of Baxter Healthcare Corporation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210309005959/en/

Contacts

Investor Relations Contact:
Ashley R. Robinson | Managing Director
LifeSci Advisors, LLC
617-430-7577 | arr@lifesciadvisors.com